RHRichard A. C. Hughes

Richard A. C. Hughes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Richard A. C. Hughes has a total of 153 co-authors. Here are the top co-authors by number of shared publications:

  • Pieter A van Doorn

    Department of Neurology, Erasmus MC, Rotterdam, The Netherlands

    8 shared publications
  • Anthony V Swan

    National Hospital for Neurology and Neurosurgery Cochrane Neuromuscular Disease Group, MRC Centre for Neuromuscular Diseases PO Box 114 London UK WC1N 3BG

    5 shared publications
  • Eduardo Nobile-Orazio

    Neuromuscular and Neuroimmunology Service, IRCCS Humanitas Clinical and Research Institute, Milan University, Italy

    4 shared publications
  • David R. Cornblath

    Organising Committee, Inflammatory Neuropathy Consortium, London, England

    3 shared publications
  • Hans-Peter Hartung

    Department of Neurology, Heinrich-Heine-University Düsseldorf, Germany

    3 shared publications
  • Jane Pritchard

    Neuromuscular Unit 3 North, Charing Cross Hospital, Fulham Palace Road, London, UK, W6 8RF

    3 shared publications

Latest Publications

  • Open Access

    Guillain‐Barré Syndrome Disability Scale

    by Richard A. C. Hughes, D. R. Cornblath, B. C. Jacobs, P. A. van Doorn


  • Open Access

    Guillain‐Barré syndrome: History, pathogenesis, treatment, and future directions

    by Richard A. C. Hughes

    Background and purpose: Since its description by Guillain, Barré, and Strohl in 1916, Guillain–Barré syndrome (GBS) has attracted a large literature. The author reviews the history of research into its pathogenesis and treatment to highlight promising avenues for future research.Methods: This is a nonsystematic personal review.Results: Since the early 1900s, the clinical picture of GBS has been illustrated in multiple series culminating in the ongoing International Guillain–Barré Syndrome study of 2000 patients. In the 1950s and 1960s, the inflammatory nature of the commonest form, acute inflammatory demyelinating polyradiculoneuropathy (AIDP), was described. In the 1990s, two axonal forms, acute motor–sensory axonal neuropathy and acute motor axonal neuropathy, were recognized. In the 1990s and early 2000s, these forms were shown to be due to antibodies against Campylobacter jejuni glycans cross‐reacting with glycolipids on axonal membranes. The pathogenesis of AIDP remains unknown, but T‐cell responses to the compact myelin proteins, P2 and P0, which cause experimental autoimmune neuritis, suggest that T cells are important. Randomized controlled trials in the 1970s and 1980s showed no benefit from corticosteroids. Trials in the 1980s showed benefit from plasma exchange and in the 1990s from intravenous immunoglobulin.Conclusions: Future research should seek biomarkers to identify subgroups with different treatment responses, define the true natural history of the disease with population‐based epidemiological studies, study the pathology in autopsies early in the disease, seek causative antibodies and confirm autoimmune T‐cell responses in AIDP, and expand treatment trials to include anti‐T‐cell agents.


  • Open Access

    An innovative phase 2 proof‐of‐concept trial design to evaluate SAR445088, a monoclonal antibody targeting complement C1s in chronic inflammatory demyelinating polyneuropathy

    by Luis Querol, Richard A. Lewis, Hans‐Peter Hartung, Pieter A. Van Doorn, Erik Wallstroem, Xiaodong Luo, Miguel Alonso‐Alonso, Nazem Atassi, Richard A. C. Hughes

    Background and Aims: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare immune‐mediated disease of the peripheral nerves, with significant unmet treatment needs. Clinical trials in CIDP are challenging; thus, new trial designs are needed. We present design of an open‐label phase 2 study (NCT04658472) evaluating efficacy and safety of SAR445088, a monoclonal antibody targeting complement C1s, in CIDP.Methods: This phase 2, proof‐of‐concept, multicenter, open‐label trial will evaluate the efficacy, and safety of SAR445088 in 90 patients with CIDP across three groups: (1) currently treated with standard‐of‐care (SOC) therapies, including immunoglobulin or corticosteroids (SOC‐Treated); (2) refractory to SOC (SOC‐Refractory); and (3) naïve to SOC (SOC‐Naïve). Enrolled participants undergo a 24‐week treatment period (part A), followed by an optional treatment extension for up to an additional 52 weeks (part B).In part A, the primary endpoint for the SOC‐Treated group is the percentage of participants with a relapse after switching from SOC to SAR445088. The primary endpoint for the SOC‐Refractory and SOC‐Naïve groups is the percentage of participants with a response, compared to baseline. Secondary endpoints include safety, tolerability, immunogenicity, and efficacy of SAR445088 during 12‐week overlapping period (SOC‐Treated). Part B evaluates long‐term safety and durability of efficacy. Data analysis will be performed using Bayesian statistics (predefined efficacy thresholds) and historical data‐based placebo assumptions to support program decision‐making.Interpretation: This innovative trial design based on patient groups and Bayesian statistics provides an efficient paradigm to evaluate new treatment candidates across the CIDP spectrum and can help accelerate development of new therapies.


  • Open Access

    Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study

    by Christine Verboon, Thomas Harbo, David R Cornblath, Richard A C Hughes, Pieter A van Doorn, Michael P Lunn, Kenneth C Gorson, Fabio Barroso, Satoshi Kuwabara, Giuliana Galassi, et al.

    Objective To compare the disease course in patients with mild Guillain-Barré syndrome (GBS) who were treated with intravenous immunoglobulin (IVIg) or supportive care only. Methods We selected patients from the prospective observational International GBS Outcome Study (IGOS) who were able to walk independently at study entry (mild GBS), treated with one IVIg course or supportive care. The primary endpoint was the GBS disability score four weeks after study entry, assessed by multivariable ordinal regression analysis. Results Of 188 eligible patients, 148 (79%) were treated with IVIg and 40 (21%) with supportive care. The IVIg group was more disabled at baseline. IVIg treatment was not associated with lower GBS disability scores at 4 weeks (adjusted OR (aOR) 1.62, 95% CI 0.63 to 4.13). Nearly all secondary endpoints showed no benefit from IVIg, although the time to regain full muscle strength was shorter (28 vs 56 days, p=0.03) and reported pain at 26 weeks was lower (n=26/121, 22% vs n=12/30, 40%, p=0.04) in the IVIg treated patients. In the subanalysis with persistent mild GBS in the first 2 weeks, the aOR for a lower GBS disability score at 4 weeks was 2.32 (95% CI 0.76 to 7.13). At 1 year, 40% of all patients had residual symptoms. Conclusion In patients with mild GBS, one course of IVIg did not improve the overall disease course. The certainty of this conclusion is limited by confounding factors, selection bias and wide confidence limits. Residual symptoms were often present after one year, indicating the need for better treatments in mild GBS.


  • Open Access

    Guillain-Barré syndrome: looking back… and forward

    by Richard A C Hughes

    The Winer and colleagues study also showed for the first time that serological evidence of recent Campylobacter jejuni and cytomegalovirus infection was more common than in hospital controls.6 C. jejuni and cytomegalovirus have now been repeatedly confirmed as precipitants. Epstein-Barr virus, hepatitis E, Mycoplasma pneumoniae, Influenza A, Haemophilus influenzae and, recently, Zika virus have been added as significant antecedent events.7 8 Interrogation of the IGOS biobank for differences in precipitants in different regions might help explain differences in the phenotype of the illness in different countries. How so many different precipitants cause an apparently similar clinical picture still defies explanation: subsequent studies have shown that GBS is a heterogeneous syndrome with different clinical patterns and different underlying pathologies.


  • Defining chronic inflammatory demyelinating polyradiculoneuropathy subtypes

    by Richard A C Hughes

    The paper by Ikeda et al is a further step in this direction.2 They classified 106 patients with CIDP, all of whom had sural nerve biopsies, into subtypes and reported their electrophysiological and pathological characteristics. In typical CIDP, nerve conduction was especially slowed in proximal and distal nerve segments, while in multifocal acquired demyelinating sensory and motor neuropathy (MADSAM) these portions were spared. The relatively minor average …


  • Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy

    by Richard Ac Hughes, Man Mohan Mehndiratta, Yusuf A Rajabally

    Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing and remitting paralysing illness, probably due to an autoimmune response, which should benefit from corticosteroid treatment. Non-randomised studies suggest that corticosteroids are beneficial. Two commonly used corticosteroids are prednisone and prednisolone. Both are usually given as oral tablets. Prednisone is converted into prednisolone in the liver so that the effect of the two drugs is usually the same. Another corticosteroid, dexamethasone, is more potent and is used in smaller doses. The review was first published in 2001 and last updated in 2015; we undertook this update to identify any new evidence. To assess the effects of corticosteroid treatment for CIDP compared to placebo or no treatment, and to compare the effects of different corticosteroid regimens. On 8 November 2016, we searched the Cochrane Neuromuscular Specialised Register, Cochrane Central Register of Controlled Trials, MEDLINE, and Embase for randomised trials of corticosteroids for CIDP. We searched clinical trials registries for ongoing trials. We included randomised controlled trials (RCTs) or quasi-RCTs of treatment with any corticosteroid or adrenocorticotrophic hormone for CIDP, diagnosed by an internationally accepted definition. Two authors extracted data from included studies and assessed the risk of bias independently. The intended primary outcome was change in disability, with change in impairment after 12 weeks and side effects as secondary outcomes. We assessed strength of evidence using the GRADE approach. One non-blinded RCT comparing prednisone with no treatment in 35 eligible participants did not measure the primary outcome for this systematic review. The trial had a high risk of bias. Neuropathy Impairment Scale scores after 12 weeks improved in 12 of 19 participants randomised to prednisone, compared with five of 16 participants randomised to no treatment (risk ratio (RR) for improvement 2.02 (95% confidence interval (CI) 0.90 to 4.52; very low-quality evidence). The trial did not report side effects in detail, but one prednisone-treated participant died. A double-blind RCT comparing daily standard-dose oral prednisolone with monthly high-dose oral dexamethasone in 40 participants reported none of the prespecified outcomes for this review. The trial had a low risk of bias, but the quality of evidence was limited as it came from a single small study. There was little or no difference in number of participants who achieved remission (RR 1.11; 95% CI 0.50 to 2.45 in favour of monthly dexamethasone; moderate-quality evidence), or change in disability or impairment after one year (low-quality evidence). Change of grip strength or Medical Research Council (MRC) scores demonstrated little or no difference between groups (moderate-quality to low-quality evidence). Eight of 16 people in the prednisolone group and seven of 24 people in the dexamethasone group deteriorated. Side effects were similar with each regimen, except that sleeplessness was less common with monthly dexamethasone (low-quality evidence) as was moon facies (moon-shaped appearance of the face) (moderate-quality evidence). Experience from large non-randomised studies suggests that corticosteroids are beneficial, but long-term use causes serious side effects. We are very uncertain about the effects of oral prednisone compared with no treatment, because the quality of evidence from the only RCT that exists is very low. Nevertheless, corticosteroids are commonly used in practice, supported by very low-quality evidence from observational studies. We also know from observational studies that corticosteroids carry the long-term risk of serious side effects. The efficacy of high-dose monthly oral dexamethasone is probably little different from that of daily standard-dose oral prednisolone. Most side effects occurred with similar frequencies in both groups, but with high-dose monthly oral dexamethasone moon facies is probably less common and sleeplessness may be less common than with oral prednisolone. We need further research to identify factors that predict response.


  • Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome

    by Jane Pritchard, Richard Ac Hughes, Robert Dm Hadden, Ruth Brassington

    Plasma exchange and intravenous immunoglobulin, but not corticosteroids, are beneficial in Guillain-Barré syndrome (GBS). The efficacy of other pharmacological agents is unknown. This review was first published in 2011 and updated in 2013 and 2016. To assess the effects of pharmacological agents other than plasma exchange, intravenous immunoglobulin and corticosteroids for GBS. On 18 January 2016, we searched the Cochrane Neuromuscular Specialised Register, Cochrane Central Register of Controlled Trials, MEDLINE, and Embase for treatments for GBS. We also searched clinical trials registries. We included all randomised controlled trials (RCTs) or quasi-RCTs of acute GBS (within four weeks from onset) of all types and degrees of severity, and in individuals of all ages. We discarded trials that investigated only corticosteroids, intravenous immunoglobulin or plasma exchange. We included other pharmacological treatments or combinations of treatments compared with no treatment, placebo or another treatment. We also identified a number of non-randomised studies during the search, the results of which we considered in the Discussion. We followed standard Cochrane methodology. We identified no new trials during this update of the review. In previous versions of this review we identified only very low quality evidence for four different interventions published in four studies. Each study had a high risk of bias in at least one respect. One RCT with 19 participants comparing interferon beta-1a and placebo showed no clinically important difference in any outcome between groups. Another with 10 participants comparing brain-derived neurotrophic factor and placebo showed no clinically important difference in any outcome between groups. A third with 37 participants comparing cerebrospinal fluid filtration and plasma exchange also showed no clinically important difference in any outcome between groups. In a fourth with 43 participants, the risk ratio for an improvement by one or more disability grade after eight weeks was greater with the Chinese herbal medicine tripterygium polyglycoside than with corticosteroids (risk ratio 1.47; 95% confidence interval 1.02 to 2.11); other outcomes in this trial showed no difference. Serious adverse events were uncommon with each of these treatments and in the control groups. The quality of the evidence was very low. Three small RCTs, comparing interferon beta-1a or brain-derived neurotrophic factor with placebo, and cerebrospinal fluid filtration with plasma exchange, showed no significant benefit or harm for any of the interventions. A fourth small trial showed that the Chinese herbal medicine, tripterygium polyglycoside, hastened recovery in people with GBS to a greater extent than corticosteroids, but this result needs confirmation. We were unable to draw any useful conclusions from the few observational studies we identified.


  • Corticosteroids for Guillain-Barré syndrome

    by Richard Ac Hughes, Ruth Brassington, Angela A Gunn, Pieter A van Doorn

    Guillain-Barré syndrome (GBS) is an acute paralysing disease caused by inflammation of the peripheral nerves, which corticosteroids would be expected to benefit. To examine the ability of corticosteroids to hasten recovery and reduce the long-term morbidity from GBS. On 12 January 2016, we searched the Cochrane Neuromuscular Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and Embase. We also searched trials registries. We included randomised controlled trials (RCTs) or quasi-RCTs of any form of corticosteroid or adrenocorticotrophic hormone versus placebo or supportive care alone in GBS. Our primary outcome was change in disability grade on a seven-point scale after four weeks. Secondary outcomes included time from randomisation until recovery of unaided walking, time from randomisation until discontinuation of ventilation (for those ventilated), death, death or disability (inability to walk without aid) after 12 months, relapse, and adverse events. The review authors used standard methods expected by Cochrane. The review authors discovered no new trials in the new searches in June 2009, November 2011, or January 2016. Six trials with 587 participants provided data for the primary outcome. According to moderate quality evidence, the disability grade change after four weeks in the corticosteroid groups was not significantly different from that in the control groups, mean difference (MD) 0.36 less improvement (95% confidence intervals (CI) 0.16 more to 0.88 less improvement). In four trials of oral corticosteroids with 120 participants in total, there was very low quality evidence of less improvement after four weeks with corticosteroids than without corticosteroids, MD 0.82 disability grades less improvement (95% CI 0.17 to 1.47 grades less). In two trials with a combined total of 467 participants, there was moderate quality evidence of no significant difference of a disability grade more improvement after four weeks with intravenous corticosteroids (MD 0.17, 95% CI -0.06 to 0.39). According to moderate quality evidence, there was also no significant difference between the corticosteroid treated and control groups for improvement by one or more grades after four weeks (risk ratio (RR) 1.08, 95% CI 0.93 to 1.24) or for death or disability after one year (RR 1.51, 95% CI 0.91 to 2.5). We found high quality evidence that the occurrence of diabetes was more common (RR 2.21, 95% CI 1.19 to 4.12) and hypertension less common (RR 0.15, 95% CI 0.05 to 0.41) in the corticosteroid-treated participants. According to moderate quality evidence, corticosteroids given alone do not significantly hasten recovery from GBS or affect the long-term outcome. According to very low quality evidence, oral corticosteroids delay recovery. Diabetes requiring insulin was more common and hypertension less common with corticosteroids based on high quality evidence.